A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients \>=18 years of age;
histologically documented, locally advanced , recurrent or metastatic NSCLC;
measurable disease;
no disease progression after 4 cycles of platinum-based chemotherapy.
You may not be if
unstable systemic disease;
any other malignancies in the last 5 years.
Clareo Health | A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
